logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Amunix Pharmaceuticals, Inc


USPTO Granted Patents = 11


Trademarks = 3

Forward Citations = 16

Loading Chart...
Loading Chart...

33 inventors (with patents filed for the assignee):

goldMedal Volker Schellenberger (11 out of 68 patents)

silverMedal Bee-Cheng Sim (4 out of 5 patents)

bronzeMedal Eric Johansen (4 out of 5 patents)

4.  Fan Yang (3 out of 31 patents)

5.  Joshua A Silverman (3 out of 56 patents)

6.  Benjamin Spink (3 out of 15 patents)

7.  Nathan C Geething (3 out of 20 patents)

8.  Chia-wei Wang (3 out of 25 patents)

9.  Desiree Thayer (3 out of 3 patents)

10.  Chia-Wei Wang (3 out of 3 patents)

11.  Jeffrey L Cleland (2 out of 47 patents)

12.  Willem P Stemmer (2 out of 40 patents)

13.  Wayne To (2 out of 18 patents)

14.  Vladimir Podust (2 out of 10 patents)

15.  Angela Henkensiefken (2 out of 2 patents)


11 patents:

1. 12617815 - Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same (2026-05-05),
2. 12590159 - Compositions targeting epidermal growth factor receptor and methods for making and using the same (2026-03-31),
3. 12428494 - Compositions targeting prostate-specific membrane antigen and methods for making and using the same (2025-09-30),
4. 12215156 - HER-2 targeted bispecific compositions and methods for making and using the same (2025-02-04),
5. 12071456 - Extended recombinant polypeptides and compositions comprising same (2024-08-27),
6. 12060424 - Release segments and binding compositions comprising same (2024-08-13),
7. 11981744 - Chimeric polypeptide assembly and methods of making and using the same (2024-05-14),
8. 11713358 - Chimeric polypeptide assembly and methods of making and using the same (2023-08-01),
9. 10961287 - Extended recombinant polypeptides and compositions comprising same (2021-03-30),
10. 10953073 - XTEN conjugate compositions and methods of making same (2021-03-23),
11. 10870874 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2020-12-22),
Company Overview
Amunix Pharmaceuticals, Inc. is a biotechnology company based in South San Francisco, California, specializing in the development of innovative therapeutics for the treatment of cancer and other serious diseases. The company focuses on its proprietary XTEN technology platform, which enables the design of protein therapeutics with enhanced properties, including improved stability and reduced immunogenicity. Amunix aims to advance its pipeline of product candidates through rigorous research and development, contributing to the evolving landscape of targeted therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

11 Patents

#98 in South San Francisco, CA

#6,532 in California

#27,490 in US

#51,714 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Amunix Pharmaceuticals, Inc

Forward Citations = 16

33 inventors:

goldMedal Volker Schellenberger (11 out of 68 patents)

silverMedal Bee-Cheng Sim (4 out of 5 patents)

bronzeMedal Eric Johansen (4 out of 5 patents)

4.  Fan Yang (3 out of 31 patents)

5.  Joshua A Silverman (3 out of 56 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amunix Pharmaceuticals, Inc. Retrieved from https://idiyas.com/company/amunix-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…